Search Results - "Haas, S L de"

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer by Miles, D W, de Haas, S L, Dirix, L Y, Romieu, G, Chan, A, Pivot, X, Tomczak, P, Provencher, L, Cortés, J, Delmar, P R, Scherer, S J

“…Background: Combining bevacizumab with first-line chemotherapy significantly improves progression-free survival (PFS) in HER2-negative metastatic breast cancer…”
Get full text

Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects by de Haas, SL, Schoemaker, RC, van Gerven, JMA, Hoever, P, Cohen, AF, Dingemanse, J

“…Zolpidem is one of the most frequently prescribed hypnotics, as it is a very short-acting compound with relatively few side effects. Zolpidem’s short duration…”
Get full text

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study by Martin, M., Fumoleau, P., Dewar, J.A., Albanell, J., Limentani, S.A., Campone, M., Chang, J.C., Patre, M., Strasak, A., de Haas, S.L., Xu, J., Garcia-Saenz, J.A.

“…Trastuzumab emtansine (T-DM1) exhibited enhanced antitumor activity when combined with docetaxel or pertuzumab in preclinical studies. This phase Ib/IIa study…”
Get full text

Local nitric oxide release does not affect tachyphylaxis to angiotensin II in dorsal hand veins in man in the presence of prostaglandin synthesis inhibition by de Haas, S. L., Wilkinson, I. B., Boyd, J. L., Webb, D. J.

“…Aims  Local prostaglandin (PG) production contributes to tachyphylaxis to angiotensin II (ANGII) in veins. Our aim was to assess the hypothesis that local…”
Get full text

The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol by de Haas, SL, Zoethout, RWM, Van Dyck, K, De Smet, M, Rosen, LB, Murphy, MG, Gottesdiener, KM, Schoemaker, RC, Cohen, AF, van Gerven, JMA

“…Essential tremor (ET) is a relatively frequent neurological disorder that responds in some patients to gamma-aminobutyric acid A (GABAA) agonists such as the…”
Get full text

The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A 2,3 selective agonist, in comparison with lorazepam in healthy volunteers by de Haas, SL, Franson, KL, Schmitt, JAJ, Cohen, AF, Fau, JB, Dubruc, C, van Gerven, JMA

“…Abstract Benzodiazepines are effective short-term treatments for anxiety disorders, but their use is limited by undesirable side effects related to Central…”
Get full text

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA α2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers by de Haas, S.L., de Visser, S.J., van der Post, J.P., de Smet, M., Schoemaker, R.C., Rijnbeek, B., Cohen, A.F., Vega, J.M., Agrawal, N.G.B., Goel, T.V., Simpson, R.C., Pearson, L.K., Li, S., Hesney, M., Murphy, M.G., van Gerven, J.M.A.

“…TPA023, a GABAA α2,3 αsubtype-selective partial agonist, is expected to have comparable anxiolytic efficacy as benzodiazepines with reduced sedating effects…”
Get full text

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA α2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers by de Haas, S.L., de Visser, S.J., van der Post, J.P., Schoemaker, R.C., van Dyck, K., Murphy, M.G., de Smet, M., Vessey, L.K., Ramakrishnan, R., Xue, L., Cohen, A.F., van Gerven, J.M.A.

“…The use of non-selective γ-aminobutyric acid (GABA) enhancers, such as benzodiazepines in the treatment of anxiety disorders is still widespread but hampered…”
Get full text

MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers by Boot, J.D, De Haas, S.L, Van Gerven, J.M.A, De Smet, M, Leathem, T, Wagner, J, Denker, A, Miller, D, Van Doorn, M.B.A, Schoemaker, R.C, Cohen, A.F, Diamant, Z

“…Abstract Background MK-0873 is a novel selective phosphodiesterase-4 inhibitor, which has been in development for the treatment of chronic obstructive…”
Get full text

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study super() by Martin, M, Fumoleau, P, Dewar, J A, Albanell, J, Limentani, S A, Campone, M, Chang, J C, Patre, M, Strasak, A, de Haas, S L, Xu, J, Garcia-Saenz, J A

“…In this phase Ib/IIa study, trastuzumab emtansine (T-DM1) plus docetaxel with/without pertuzumab appeared efficacious in patients with human epidermal growth…”
Get full text

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers by de Haas, S L, de Visser, S J, van der Post, J P, de Smet, M, Schoemaker, R C, Rijnbeek, B, Cohen, A F, Vega, J M, Agrawal, N G B, Goel, T V, Simpson, R C, Pearson, L K, Li, S, Hesney, M, Murphy, M G, van Gerven, J M A

“…TPA023, a GABA(A) alpha2,3 alphasubtype-selective partial agonist, is expected to have comparable anxiolytic efficacy as benzodiazepines with reduced sedating…”
Get full text

Abstract P6-07-09: Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC) by de Haas, SL, Hurvitz, SA, Martin, M, Kiermaier, A, Lewis Phillips, G, Xu, J, Helms, H-J, Slamon, D, Press, MF

“…Abstract Introduction KRISTINE (NCT02131064) is an open-label, phase 3 study of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) vs docetaxel +…”
Get full text

Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC) by Prat, A, Slamon, D, Hurvitz, SA, Press, MF, Lewis Phillips, G, Lopez Valverde, V, Kiermaier, A, Helms, H-J, Martin, M, de Haas, SL

“…Abstract Introduction: Previous studies have shown that HER2+ breast cancer is biologically heterogenous and intrinsic subtypes can be identified (luminal A,…”
Get full text

Venous infarction of the testis--a cause of non-response to conservative therapy in epididymo-orchitis. A case report by Rencken, R K, du Plessis, D J, de Haas, L S

“…Acute epididymo-orchitis occasionally responds poorly to conservative measures. Testicular infarction may be one reason for this complication. Ultrasonography…”
Get full text

Abstract P1-09-05: The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC) by Harbeck, N, Nitz, UA, Matthias, C, Kates, R, Braun, M, Kümmel, S, Schumacher, C, Potenberg, J, Kraemer, S, Kleine-Tebbe, A, Augustin, D, Aktas, B, Forstbauer, H, Tio, J, Liedtke, C, Grischke, E-M, de Haas, SL, Deurloo, R, Schumacher, J, Wuerstlein, R, Kreipe, HH, Gluz, O

“…Abstract Background: Immune and apoptosis biomarkers are potential prognostic/predictive markers in HER2+ EBC. High PD-L1 expression was shown to be predictive…”
Get full text

The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers by de Haas, S L, Franson, K L, Schmitt, J A J, Cohen, A F, Fau, J B, Dubruc, C, van Gerven, J M A

“…Benzodiazepines are effective short-term treatments for anxiety disorders, but their use is limited by undesirable side effects related to Central Nervous…”
Get full text

Abstract S5-03: Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer by Harbeck, N, Gluz, O, Christgen, M, Braun, M, Kuemmel, S, Schumacher, C, Potenberg, J, Kraemer, S, Kleine-Tebbe, A, Augustin, D, Aktas, B, Forstbauer, H, Tio, J, Liedtke, C, Kates, RE, Wuerstlein, R, de Haas, SL, Kiermaier, A, Kreipe, HH, Nitz, U

“…Abstract Background: In HER2+ early breast cancer (eBC) pCR rates after standard neoadjuvant chemo- + anti-HER2 therapy differ according to hormone-receptor…”
Get full text

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA alpha2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers by de Haas, S L, de Visser, S J, J P van der Post, de Smet, M

“…TPA023, a GABAA alpha2,3 subtype-selective partial agonist, is expected to have comparable anxiolytic efficacy as benzodiazepines with reduced sedating…”
Get full text

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers by de Haas, S L, de Visser, S J, van der Post, J P, Schoemaker, R C, van Dyck, K, Murphy, M G, de Smet, M, Vessey, L K, Ramakrishnan, R, Xue, L, Cohen, A F, van Gerven, J M A

“…The use of non-selective gamma-aminobutyric acid (GABA) enhancers, such as benzodiazepines in the treatment of anxiety disorders is still widespread but…”
Get full text

Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA^sub A^ [alpha]^sub 2,3^ subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers by Haas, S L de, Visser, S J de, Post, J P van der, Schoemaker, R C, Dyck, K van, Murphy, M G, Smet, M de, Vessey, L K, Ramakrishnan, R, Xue, L, Cohen, A F, Gerven, J M A van

“…The use of non-selective y-aminobutyric acid (GABA) enhancers, such as benzodiazepines in the treatment of anxiety disorders is still widespread but hampered…”
Get full text